Skip to main content
VCbacked
Log inGet Started

Novelty Nobility

Seongnam, South Korea

Novelty Nobility is a private biotech company focused on the research of novel angiogenesis targets and develop antibody-based therapeutics.

$16.6M raised
Nov 2024
Series C
BiotechnologyHealth CareLife ScienceTherapeutics

Top Investors

HB InvestmentSGI Venture CapitalSL InvestmentTIPS ProgramShinhan Venture Investment

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Novelty Nobility

How much funding has Novelty Nobility raised?
Novelty Nobility has raised $16.6M in total funding. The most recent round was Series C. The last funding was announced in November 2024.
Who are Novelty Nobility's investors?
Novelty Nobility's investors include HB Investment, SGI Venture Capital, SL Investment, TIPS Program, Shinhan Venture Investment.
Where is Novelty Nobility headquartered?
Novelty Nobility is headquartered in Seongnam, South Korea.
What does Novelty Nobility do?
Novelty Nobility is a private biotech company focused on the research of novel angiogenesis targets and develop antibody-based therapeutics.
What stage is Novelty Nobility at?
Novelty Nobility is at the Series C stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Novelty Nobility — Funding & Investors." VCBacked, November 11, 2024, https://www.vcbacked.co/company/novelty-nobility. Accessed June 4, 2026.
APA
VCBacked. (2024). Novelty Nobility — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/novelty-nobility
Wikipedia (cite web)
{{cite web |title=Novelty Nobility — Funding & Investors |url=https://www.vcbacked.co/company/novelty-nobility |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong